MiREnDa 2014.
Study characteristics | ||
Methods |
|
|
Participants |
|
|
Interventions | Treatment group
Control group
|
|
Outcomes |
|
|
Identification |
|
|
Notes |
|
|
Risk of bias | ||
Bias | Authors' judgement | Support for judgement |
Random sequence generation (selection bias) | Low risk | Quote: "patients were randomly allocated 1:1 to either 50 mg spironolactone once daily or matching placebo using an algorithm for balanced randomised assignment for stratified randomizations." |
Allocation concealment (selection bias) | Low risk | Quote: "patients were randomly allocated 1:1 to either 50 mg spironolactone once daily or matching placebo using an algorithm for balanced randomised assignment for stratified randomizations." |
Blinding of participants and personnel (performance bias) All outcomes | Low risk | Quote: "MiREnDa was an investigator‐initiated, randomised, double‐blind, placebo‐ controlled trial to study the efficacy and safety of spironolactone in HD patients." |
Blinding of outcome assessment (detection bias) All outcomes | Low risk | Quote: "MiREnDa was an investigator‐initiated, randomised, double‐blind, placebo‐ controlled trial" |
Incomplete outcome data (attrition bias) All outcomes | Low risk | Missing outcome data balanced across intervention groups |
Selective reporting (reporting bias) | Low risk | All prespecified outcomes have been reported in ClinicalTrials.gov identifier NCT01691053 |
Other bias | Low risk | The MiREnDa trial was funded by the German Federal Ministry of Education and Research (01KG1202) and conducted under the auspices of the German Society of Nephrology. Additional funding was obtained from E.N.D.I.—the European Nephrology and Dialysis Institute |